Pharmaceutical manufacturing

January 22, 2018 - 3:39 am
PARIS (AP) — France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases. The deal announced Monday is the latest such move in a pharmaceutical industry that's seeing increasing interest...
Read More
January 08, 2018 - 12:52 pm
HELSINKI (AP) — Danish drugmaker Novo Nordisk has revised up its offer for Belgian biotech company Ablynx as it looks to find growth opportunities beyond its core business. The Copenhagen-based company said Monday it is offering up to 30.50 euros for each Ablynx share, valuing the company at around...
Read More
FILE - In this Oct. 4, 2017, file photo, Dr. Albert Maguire, right, checks the eyes of Misa Kaabali, 8, at the Children's Hospital of Philadelphia. Misa was 4-years-old when he received his gene therapy treatment. The first-of-its kind genetic treatment for blindness will cost $850,000, less than the $1 million price tag that had been expected, but it's still among the most expensive genetic therapies in the world. Spark Therapeutics said it decided on the lower price tag for Luxturna, after hearing from health insurers about their ability to cover the injectable treatment. (AP Photo/Bill West, File)
January 03, 2018 - 6:22 pm
WASHINGTON (AP) — A first-of-its kind genetic treatment for blindness will cost $850,000 per patient, making it one of the most expensive medicines in the world and raising questions about the affordability of a coming wave of similar gene-targeting therapies. The injectable treatment from Spark...
Read More
FILE - In this Oct. 4, 2017, file photo, Dr. Albert Maguire, right, checks the eyes of Misa Kaabali, 8, at the Children's Hospital of Philadelphia. Misa was 4-years-old when he received his gene therapy treatment. The first-of-its kind genetic treatment for blindness will cost $850,000, less than the $1 million price tag that had been expected, but it's still among the most expensive genetic therapies in the world. Spark Therapeutics said it decided on the lower price tag for Luxturna, after hearing from health insurers about their ability to cover the injectable treatment. (AP Photo/Bill West, File)
January 03, 2018 - 12:09 pm
WASHINGTON (AP) — A first-of-its kind genetic treatment for blindness will cost $850,000, less than the $1 million price tag that had been expected, but still among the most expensive medicines in the world. Spark Therapeutics said Wednesday it decided on the lower price for Luxturna (Lux-turn-a)...
Read More
January 03, 2018 - 8:39 am
WASHINGTON (AP) — A first-of-its kind genetic treatment for blindness will cost $850,000, less than the $1 million price tag that had been expected, but it's still among the most expensive genetic therapies in the world. Spark Therapeutics says it decided on the lower price tag for Luxturna (Lux-...
Read More
January 03, 2018 - 8:36 am
WASHINGTON (AP) — A first-of-its kind genetic treatment for blindness will cost $850,000, less than the $1 million price tag that had been expected, but it's still among the most expensive genetic therapies in the U.S. world? Spark Therapeutics says it decided on the lower price tag for Luxturna (...
Read More
Stock trader Chris Lotito studies a computer screen at the New York Stock Exchange, Tuesday, Jan. 2, 2018. (AP Photo/Mark Lennihan)
January 02, 2018 - 5:42 pm
NEW YORK (AP) — Technology and health care companies jumped Tuesday as U.S. stocks started the new year the same way they spent the last one: rising steadily and setting records. Energy companies, which struggled in 2017, also climbed. Asian markets rose after surveys in China and India showed...
Read More
Stock trader Chris Lotito studies a computer screen at the New York Stock Exchange, Tuesday, Jan. 2, 2018. (AP Photo/Mark Lennihan)
January 02, 2018 - 3:33 pm
NEW YORK (AP) — Technology and health care companies are jumping Tuesday as U.S. stocks start the new year the same way they spent the last one: rising steadily and setting records. Energy companies, which struggled in 2017, also climbed higher. Bond yields are climbing and high-dividend companies...
Read More
Stock trader Chris Lotito studies a computer screen at the New York Stock Exchange, Tuesday, Jan. 2, 2018. (AP Photo/Mark Lennihan)
January 02, 2018 - 12:23 pm
NEW YORK (AP) — U.S. stocks are starting the new year higher thanks in part to gains in technology and health care companies, some of the market's biggest winners from 2017. Retailers are also up. Natural gas prices are rising as cold weather continues to grip much of the U.S. Bond yields are...
Read More
Stock trader Chris Lotito studies a computer screen at the New York Stock Exchange, Tuesday, Jan. 2, 2018. (AP Photo/Mark Lennihan)
January 02, 2018 - 11:16 am
NEW YORK (AP) — U.S. stocks are starting the new year higher thanks in part to gains in technology and health care companies, some of the market's biggest winners from 2017. Retailers are up as well. Natural gas prices are rising as cold weather continues to grip much of the U.S. Bond yields are...
Read More

Pages